2023 annual financial data
China SXT Pharmaceuticals 2023 Operating margin
China SXT Pharmaceuticals 2023 operating margin with verified reported values.
Direct answer
Operating margin was -284.4%.
Operating income was -5,607,509 USD and net income was -5,934,772 USD.
Operating cash flow was -80,757 USD.
Get free China SXT Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,971,679 USD
- Operating income
- -5,607,509 USD
- Net income
- -5,934,772 USD
- Operating cash flow
- -80,757 USD